Announcements
- Addex’s Partner Discontinues ADX71149 development in Epilepsy
- Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
- Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
- Addex Convenes Annual General Meeting 2024
- Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.064 |
Average volume | -- |
---|---|
Shares outstanding | 184.35m |
Free float | 150.65m |
P/E (TTM) | -- |
Market cap | 11.58m CHF |
EPS (TTM) | -0.1116 CHF |
Data delayed at least 20 minutes, as of May 02 2024.
More ▼